NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
Business Wire (Fri, 19-Apr 6:00 PM ET)
NovaBay Pharmaceuticals show 13% rise in eyecare and wound care segment - prelim report
Seeking Alpha News (Wed, 17-Apr 7:23 AM ET)
Business Wire (Wed, 17-Apr 6:59 AM ET)
Buy Rating Maintained for NovaBay Pharma Amid Strategic Refocus and Resilient Revenue Performance
TipRanks (Mon, 15-Apr 5:16 AM ET)
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
Business Wire (Tue, 26-Mar 4:05 PM ET)
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
Business Wire (Mon, 25-Mar 6:38 PM ET)
Business Wire (Thu, 14-Mar 8:00 AM ET)
Globe Newswire (Wed, 13-Mar 7:00 AM ET)
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
Business Wire (Tue, 30-Jan 9:00 AM ET)
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
Novabay Pharmaceuticals trades on the AMEX stock market under the symbol NBY.
As of April 19, 2024, NBY stock price was flat at $0.08 with 1,406,814 million shares trading.
NBY has a beta of 0.77, meaning it tends to be less sensitive to market movements. NBY has a correlation of 0.02 to the broad based SPY ETF.
NBY has a market cap of $2.48 million. This is considered a Sub-Micro Cap stock.
Last quarter Novabay Pharmaceuticals reported $4 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $327,000 and exceeded earnings estimates by $.09.
In the last 3 years, NBY stock traded as high as $30.70 and as low as $.07.
The top ETF exchange traded funds that NBY belongs to (by Net Assets): VXF.
NBY has underperformed the market in the last year with a price return of -95.2% while the SPY ETF gained +21.2%. NBY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.8% and -21.2%, respectively, while the SPY returned +4.3% and -3.5%, respectively.
NBY support price is $.08 and resistance is $.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBY stock will trade within this expected range on the day.